

**General information about company**

Scrip code	531592
NSE Symbol	
MSEI Symbol	
ISIN*	INE861N01036
Name of company	Genpharmasec Limited
Type of company	
Class of security	Equity
Date of start of financial year	01-04-2024
Date of end of financial year	31-03-2025
Date of board meeting when results were approved	13-08-2024
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	05-08-2024
Description of presentation currency	INR
Level of rounding used in financial results	Lakhs
Reporting Quarter	First quarter
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited	Unaudited
Segment Reporting	Multi segment
Description of single segment	
Start date and time of board meeting	13-08-2024 14:30
End date and time of board meeting	13-08-2024 17:50
Whether cash flow statement is applicable on company	
Type of cash flow statement	
Declaration of unmodified opinion or statement on impact of audit qualification	Not applicable

<b>Financial Results - Ind-AS</b>			
<b>Particulars</b>		<b>3 months/ 6 months ended (dd-mm-yyyy)</b>	<b>Year to date figures for current period ended (dd-mm-yyyy)</b>
A	Date of start of reporting period	01-04-2024	01-04-2024
B	Date of end of reporting period	30-06-2024	30-06-2024
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
<b>Part I</b>	<b>Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.</b>		
<b>1</b>	<b>Income</b>		
	Revenue from operations	530.289	530.289
	Other income	57.794	57.794
	<b>Total income</b>	<b>588.083</b>	<b>588.083</b>
<b>2</b>	<b>Expenses</b>		
(a)	Cost of materials consumed	0	0
(b)	Purchases of stock-in-trade	547.336	547.336
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-119.106	-119.106
(d)	Employee benefit expense	17.288	17.288
(e)	Finance costs	7.114	7.114
(f)	Depreciation, depletion and amortisation expense	0.492	0.492
<b>(f)</b>	<b>Other Expenses</b>		
1	Other Expenses	61.76	61.76
10			
	<b>Total other expenses</b>	<b>61.76</b>	<b>61.76</b>
	<b>Total expenses</b>	<b>514.884</b>	<b>514.884</b>

<b>Financial Results - Ind-AS</b>			
<b>Particulars</b>		<b>3 months/ 6 months ended (dd-mm-yyyy)</b>	<b>Year to date figures for current period ended (dd-mm-yyyy)</b>
A	Date of start of reporting period	01-04-2024	01-04-2024
B	Date of end of reporting period	30-06-2024	30-06-2024
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
<b>Part I</b>	<b>Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.</b>		
<b>3</b>	<b>Total profit before exceptional items and tax</b>	73.199	73.199
4	Exceptional items	0	0
<b>5</b>	<b>Total profit before tax</b>	73.199	73.199
<b>7</b>	<b>Tax expense</b>		
8	Current tax	0	0
9	Deferred tax	14.325	14.325
<b>10</b>	<b>Total tax expenses</b>	14.325	14.325
11	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
<b>14</b>	<b>Net Profit Loss for the period from continuing operations</b>	58.874	58.874
15	Profit (loss) from discontinued operations before tax	0	0
16	Tax expense of discontinued operations	0	0
<b>17</b>	<b>Net profit (loss) from discontinued operation after tax</b>	0	0
19	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
<b>21</b>	<b>Total profit (loss) for period</b>	58.874	58.874

## Financial Results - Ind-AS

Particulars		3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-04-2024	01-04-2024
B	Date of end of reporting period	30-06-2024	30-06-2024
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
<b>Other comprehensive income [Abstract]</b>			
<b>1 Amount of items that will not be reclassified to profit and loss</b>			
1	Equity Instruments through FVOCI	22.42	22.42
	<b>Total Amount of items that will not be reclassified to profit and loss</b>	22.42	22.42
2	<b>Income tax relating to items that will not be reclassified to profit or loss</b>	0	0
<b>3 Amount of items that will be reclassified to profit and loss</b>			
	<b>Total Amount of items that will be reclassified to profit and loss</b>		
4	<b>Income tax relating to items that will be reclassified to profit or loss</b>	0	0
5	<b>Total Other comprehensive income</b>	22.42	22.42

<b>Financial Results - Ind-AS</b>			
<b>Particulars</b>		<b>3 months/ 6 months ended (dd-mm-yyyy)</b>	<b>Year to date figures for current period ended (dd-mm-yyyy)</b>
A	Date of start of reporting period	01-04-2024	01-04-2024
B	Date of end of reporting period	30-06-2024	30-06-2024
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
<b>Part I</b>	<b>Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.</b>		
<b>23</b>	<b>Total Comprehensive Income for the period</b>	81.294	81.294
<b>24</b>	<b>Total profit or loss, attributable to</b>		
	Profit or loss, attributable to owners of parent		
	Total profit or loss, attributable to non-controlling interests		
<b>25</b>	<b>Total Comprehensive income for the period attributable to</b>		
	Comprehensive income for the period attributable to owners of parent	0	0
	Total comprehensive income for the period attributable to owners of parent non-controlling interests	0	0
<b>26</b>	<b>Details of equity share capital</b>		
	Paid-up equity share capital	5537.2	5537.2
	Face value of equity share capital	1	1
<b>27</b>	<b>Details of debt securities</b>		
28	Reserves excluding revaluation reserve		
<b>29</b>	<b>Earnings per share</b>		
<b>i</b>	<b>Earnings per equity share for continuing operations</b>		
	Basic earnings (loss) per share from continuing operations	0.011	0.011
	Diluted earnings (loss) per share from continuing operations	0.011	0.011
<b>ii</b>	<b>Earnings per equity share for discontinued operations</b>		
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
<b>ii</b>	<b>Earnings per equity share</b>		
	<b>Basic earnings (loss) per share from continuing and discontinued operations</b>	0.011	0.011
	<b>Diluted earnings (loss) per share from continuing and discontinued operations</b>	0.011	0.011
30	Debt equity ratio	0	0
31	Debt service coverage ratio	0	0
32	Interest service coverage ratio	0	0
<b>33</b>	<b>Disclosure of notes on financial results</b>	Textual Information(1)	

## Text Block

Textual Information(1)

1. The Financial result were reviewed by the Audit Committee and approved by the Board Of directors at their meeting on 13th August, 2024.
2. The above result have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under section 133 of the Companies Act 2013, and other recognized accounting practices and policies to the extent applicable.
3. The audited report does not contain any qualification. The above Financial audited review report will be filed with the stock Exchange and will also be available on Company's website [www.genpharmasec.com](http://www.genpharmasec.com)
4. Segment Reporting has been annexed in Annexure 1.
5. The certificate of CFO in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in respect of the above results has been placed before the Board of Directors
6. The outstanding loan of Rs. 41.96 Lacs as on 31.03.24, have been provided as bad debts by the company and is included under the head 'Other Expenses' for the quarter and year ended 31.3.24.
7. The results for the quarter ended 31st March,2024 and 31st March,2023 are the balancing figure between audited figures in respect of the full financial year and the published unaudited financial results of the nine months ended 31st December ,2023 and 31st December,2022 respectively.
8. The Name of the company has been changed from Generic Pharmasec Limited to Genpharmasec Limited w.e.f 25th October,2021
9. The company has incorporated a new wholly owned subsidiary namely M/s. Clinigenome India Pvt Ltd' to expand the business activities on 29.01.2024
10. The Company has recognised the Deferred Tax Assets of Rs. 42.50 Lacs on Carried forward unabsorbed Depreciation Loss of Rs.184.50 Lacs as per income tax records on the bases of managemnet estimate of virtual certainty of Profit in future.
11. During the quarter ended 31st March, 2024; the company made investment in M/s. Derren Healthcare Pvt Ltd, (DHPL) as detailed hereunder:  
  
The Company has entered into an Share Purchase Agreement (SPA) with DHPL and its promoters on 19th September 2023 for acquiring 70% shareholding of DHPL. The Company has also simultaneously entered into a Share Subscription Cum Shareholder's Agreement' (SSSA) on the same day to and agreed to induct Rs. 5 Crores into DHPL and in turn, DHPL will allot 13,84,275 shares to the Company.  
  
The Company made payment of Rs. 12,63,95,377/- to one of the Promoters, Mr. Vibhava Kumar Singh who is holding 70% shares in DHPL for purchase of 35,00,000 shares. The Company has also inducted Rs. 5 crore in DHPL for subscription of 13,84,275 shares. These payments represent full payment towards total acquisition of 70% shareholding in DHPL and additional shareholding as envisaged in SSSA.  
  
The total acquisition is to be completed by 19th September 2024. However, M/s. Genpharmasec Ltd, the company, will gain 'controlling interest' only after complete execution of respective SPA and SSA.
12. The Company has brought forward lossess, which are set-off against the proift hence provision for current tax is not Provided.
13. The Board of Directors at its meeting held on 21st February 2024 allotted 27,68,59,850 shares to the Equity Shareholders of the Company through Right issue at issue price of Rs. 1.75 per equity Share (including a premium of Rs. 0.75 per equity Share).

<b>Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results</b>			
<b>Particulars</b>		<b>3 months/ 6 month ended (dd-mm-yyyy)</b>	<b>Year to date figures for current period ended (dd-mm-yyyy)</b>
Date of start of reporting period		01-04-2024	01-04-2024
Date of end of reporting period		30-06-2024	30-06-2024
Whether accounts are audited or unaudited		Unaudited	Unaudited
Nature of report standalone or consolidated		Standalone	Standalone
<b>1</b>	<b>Segment Revenue (Income)</b>		
	<b>(net sale/income from each segment should be disclosed)</b>		
1	Pharmaceuticals	530.289	530.289
2	Trading in Securities	0	0
	<b>Total Segment Revenue</b>	530.289	530.289
	<b>Less: Inter segment revenue</b>	0	0
	<b>Revenue from operations</b>	530.289	530.289
<b>2</b>	<b>Segment Result</b>		
	<b>Profit (+) / Loss (-) before tax and interest from each segment</b>		
1	Pharmaceuticals	79.546	79.546
2	Trading in Securities	0	0
	<b>Total Profit before tax</b>	79.546	79.546
	<b>i. Finance cost</b>	6.346	6.346
	<b>ii. Other Unallocable Expenditure net off Unallocable income</b>	0	0
	<b>Profit before tax</b>	73.2	73.2
<b>3</b>	<b>(Segment Asset - Segment Liabilities)</b>		
	<b>Segment Asset</b>		
1	Pharmaceuticals	3322.85	3322.85
2	Trading in Securities	126.03	126.03
	<b>Total Segment Asset</b>	3448.88	3448.88
	<b>Un-allocable Assets</b>	3655.29	3655.29
	<b>Net Segment Asset</b>	7104.17	7104.17
<b>4</b>	<b>Segment Liabilities</b>		
	<b>Segment Liabilities</b>		
1	Pharmaceuticals	245.07	245.07
2	Trading in Securities	0	0
	<b>Total Segment Liabilities</b>	245.07	245.07
	<b>Un-allocable Liabilities</b>	6859.1	6859.1
	<b>Net Segment Liabilities</b>	7104.17	7104.17
	<b>Disclosure of notes on segments</b>		





**General information about company**

Scrip code	531592
NSE Symbol	
MSEI Symbol	
ISIN*	INE861N01036
Name of company	Genpharmasec Limited
Type of company	
Class of security	Equity
Date of start of financial year	01-04-2024
Date of end of financial year	31-03-2025
Date of board meeting when results were approved	13-08-2024
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	05-08-2024
Description of presentation currency	INR
Level of rounding used in financial results	Lakhs
Reporting Quarter	First quarter
Nature of report standalone or consolidated	Consolidated
Whether results are audited or unaudited	Unaudited
Segment Reporting	Multi segment
Description of single segment	
Start date and time of board meeting	13-08-2024 14:30
End date and time of board meeting	13-08-2024 17:50
Whether cash flow statement is applicable on company	
Type of cash flow statement	
Declaration of unmodified opinion or statement on impact of audit qualification	Not applicable

<b>Financial Results - Ind-AS</b>			
<b>Particulars</b>		<b>3 months/ 6 months ended (dd-mm-yyyy)</b>	<b>Year to date figures for current period ended (dd-mm-yyyy)</b>
A	Date of start of reporting period	01-04-2024	01-04-2024
B	Date of end of reporting period	30-06-2024	30-06-2024
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Consolidated	Consolidated
<b>Part I</b>	<b>Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.</b>		
<b>1</b>	<b>Income</b>		
	Revenue from operations	519.498	519.498
	Other income	56.7	56.7
	<b>Total income</b>	<b>576.198</b>	<b>576.198</b>
<b>2</b>	<b>Expenses</b>		
(a)	Cost of materials consumed	0	0
(b)	Purchases of stock-in-trade	567.494	567.494
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-152.056	-152.056
(d)	Employee benefit expense	17.582	17.582
(e)	Finance costs	10.194	10.194
(f)	Depreciation, depletion and amortisation expense	15.604	15.604
<b>(f)</b>	<b>Other Expenses</b>		
1	Other Expenses	68.68	68.68
10			
	<b>Total other expenses</b>	<b>68.68</b>	<b>68.68</b>
	<b>Total expenses</b>	<b>527.498</b>	<b>527.498</b>

<b>Financial Results - Ind-AS</b>			
<b>Particulars</b>		<b>3 months/ 6 months ended (dd-mm-yyyy)</b>	<b>Year to date figures for current period ended (dd-mm-yyyy)</b>
A	Date of start of reporting period	01-04-2024	01-04-2024
B	Date of end of reporting period	30-06-2024	30-06-2024
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Consolidated	Consolidated
<b>Part I</b>	<b>Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.</b>		
<b>3</b>	<b>Total profit before exceptional items and tax</b>	48.7	48.7
4	Exceptional items	0	0
<b>5</b>	<b>Total profit before tax</b>	48.7	48.7
<b>7</b>	<b>Tax expense</b>		
8	Current tax	0	0
9	Deferred tax	20.02	20.02
<b>10</b>	<b>Total tax expenses</b>	20.02	20.02
11	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
<b>14</b>	<b>Net Profit Loss for the period from continuing operations</b>	28.68	28.68
15	Profit (loss) from discontinued operations before tax	0	0
16	Tax expense of discontinued operations	0	0
<b>17</b>	<b>Net profit (loss) from discontinued operation after tax</b>	0	0
19	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
<b>21</b>	<b>Total profit (loss) for period</b>	28.68	28.68

## Financial Results - Ind-AS

<b>Particulars</b>		3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-04-2024	01-04-2024
B	Date of end of reporting period	30-06-2024	30-06-2024
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Consolidated	Consolidated
<b>Other comprehensive income [Abstract]</b>			
<b>1 Amount of items that will not be reclassified to profit and loss</b>			
1	Equity instrument through other comprehensive income	22.42	22.42
	<b>Total Amount of items that will not be reclassified to profit and loss</b>	22.42	22.42
2	<b>Income tax relating to items that will not be reclassified to profit or loss</b>	0	0
<b>3 Amount of items that will be reclassified to profit and loss</b>			
	<b>Total Amount of items that will be reclassified to profit and loss</b>		
4	<b>Income tax relating to items that will be reclassified to profit or loss</b>	0	0
5	<b>Total Other comprehensive income</b>	22.42	22.42

<b>Financial Results - Ind-AS</b>			
<b>Particulars</b>		<b>3 months/ 6 months ended (dd-mm-yyyy)</b>	<b>Year to date figures for current period ended (dd-mm-yyyy)</b>
A	Date of start of reporting period	01-04-2024	01-04-2024
B	Date of end of reporting period	30-06-2024	30-06-2024
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Consolidated	Consolidated
<b>Part I</b>	<b>Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.</b>		
<b>23</b>	<b>Total Comprehensive Income for the period</b>	51.1	51.1
<b>24</b>	<b>Total profit or loss, attributable to</b>		
	Profit or loss, attributable to owners of parent	0	0
	Total profit or loss, attributable to non-controlling interests	0	0
<b>25</b>	<b>Total Comprehensive income for the period attributable to</b>		
	Comprehensive income for the period attributable to owners of parent	0	0
	Total comprehensive income for the period attributable to owners of parent non-controlling interests	0	0
<b>26</b>	<b>Details of equity share capital</b>		
	Paid-up equity share capital	5537.2	5537.2
	Face value of equity share capital	1	1
<b>27</b>	<b>Details of debt securities</b>		
28	Reserves excluding revaluation reserve		
<b>29</b>	<b>Earnings per share</b>		
<b>i</b>	<b>Earnings per equity share for continuing operations</b>		
	Basic earnings (loss) per share from continuing operations	0.01	0.01
	Diluted earnings (loss) per share from continuing operations	0.01	0.01
<b>ii</b>	<b>Earnings per equity share for discontinued operations</b>		
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
<b>ii</b>	<b>Earnings per equity share</b>		
	<b>Basic earnings (loss) per share from continuing and discontinued operations</b>	0.01	0.01
	<b>Diluted earnings (loss) per share from continuing and discontinued operations</b>	0.01	0.01
30	Debt equity ratio	0	0
31	Debt service coverage ratio	0	0
32	Interest service coverage ratio	0	0
<b>33</b>	<b>Disclosure of notes on financial results</b>	Textual Information(1)	

## Text Block

Textual Information(1)	<ol style="list-style-type: none"><li>1. The Financial result were reviewed by the Audit Committee and approved by the Board Of directors at their meeting on 13th August, 2024.</li><li>2. The above result have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under section 133 of the Companies Act 2013, and other recognized accounting practices and policies to the extent applicable.</li><li>3. The audited report does not contain any qualification. The above Financial audited review report will be filed with the stock Exchange and will also be available on Company's website <a href="http://www.genpharmasec.com">www.genpharmasec.com</a></li><li>4. Segment Reporting has been annexed in Annexure 1.</li><li>5. The certificate of CFO in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in respect of the above results has been placed before the Board of Directors</li><li>6. The outstanding loan of Rs. 41.96 Lacs as on 31.03.24, have been provided as bad debts by the company and is included under the head 'Other Expenses' for the quarter and year ended 31.3.24.</li><li>7. The results for the quarter ended 31st March,2024 are the balancing figure between audited figures in respect of the full financial year and the published unaudited financial results of the nine months ended 31st December ,2023.</li><li>8. The Name of the company has been changed from Generic Pharmasec Limited to Genpharmasec Limited w.e.f 25th October,2021</li><li>9. The company has incorporated a new wholly owned subsidiary namely M/s. Clinigenome India Pvt Ltd' to expand the business activities on 29.01.2024. Thus the consolidated figures as on 30th June 2023 are NIL</li><li>10. The Company has recognised the Deferred Tax Assets of Rs. 42.50 Lacs on Carried forward unabsorbed Depreciation Loss of Rs.184.50 Lacs as per income tax records on the bases of managemnet estimate of virtual certainty of Profit in future.</li><li>11. During the quarter ended 31st March, 2024; the company made investment in M/s. Derren Healthcare Pvt Ltd, (DHPL) as detailed hereunder:  The Company has entered into an Share Purchase Agreement (SPA) with DHPL and its promoters on 19th September 2023 for acquiring 70% shareholding of DHPL. The Company has also simultaneously entered into a Share Subscription Cum Shareholder's Agreement' (SSSA) on the same day to and agreed to induct Rs. 5 Crores into DHPL and in turn, DHPL will allot 13,84,275 shares to the Company.  The Company made payment of Rs. 12,63,95,377/- to one of the Promoters, Mr. Vibhava Kumar Singh who is holding 70% shares in DHPL for purchase of 35,00,000 shares. The Company has also inducted Rs. 5 crore in DHPL for subscription of 13,84,275 shares. These payments represent full payment towards total acquisition of 70% shareholding in DHPL and additional shareholding as envisaged in SSSA.  The total acquisition is to be completed by 19th September 2024. However, M/s. Genpharmasec Ltd, the company, will gain 'controlling interest' only after complete execution of respective SPA and SSA.</li><li>12. The Company has brought forward lossess, which are set-off against the proift hence provision for current tax is not Provided.</li><li>13. The Board of Directors at its meeting held on 21st February 2024 allotted 27,68,59,850 shares to the Equity Shareholders of the Company through Right issue at issue price of Rs. 1.75 per equity Share (including a premium of Rs. 0.75 per equity Share).</li></ol>
------------------------	--

<b>Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results</b>			
<b>Particulars</b>		<b>3 months/ 6 month ended (dd-mm-yyyy)</b>	<b>Year to date figures for current period ended (dd-mm-yyyy)</b>
Date of start of reporting period		01-04-2024	01-04-2024
Date of end of reporting period		30-06-2024	30-06-2024
Whether accounts are audited or unaudited		Unaudited	Unaudited
Nature of report standalone or consolidated		Consolidated	Consolidated
<b>1</b>	<b>Segment Revenue (Income)</b>		
	<b>(net sale/income from each segment should be disclosed)</b>		
1	Pharmaceuticals	530.289	530.289
2	Trading in Securities	0	0
3	Laboratory Testing	3.66	3.66
	<b>Total Segment Revenue</b>	533.949	533.949
	<b>Less: Inter segment revenue</b>	0	0
	<b>Revenue from operations</b>	533.949	533.949
<b>2</b>	<b>Segment Result</b>		
	<b>Profit (+) / Loss (-) before tax and interest from each segment</b>		
1	Pharmaceuticals	79.546	79.546
2	Trading in Securities	0	0
3	Laboratory Testing	-20.3	-20.3
	<b>Total Profit before tax</b>	59.246	59.246
	<b>i. Finance cost</b>	10.59	10.59
	<b>ii. Other Unallocable Expenditure net off Unallocable income</b>	0	0
	<b>Profit before tax</b>	48.656	48.656
<b>3</b>	<b>(Segment Asset - Segment Liabilities)</b>		
	<b>Segment Asset</b>		
1	Pharmaceuticals	3273.41	3273.41
2	Trading in Securities	126.03	126.03
3	Laboratory Testing	615.42	615.42
	<b>Total Segment Asset</b>	4014.86	4014.86
	<b>Un-allocable Assets</b>	3275.01	3275.01
	<b>Net Segment Asset</b>	7289.87	7289.87
<b>4</b>	<b>Segment Liabilities</b>		
	<b>Segment Liabilities</b>		
1	Pharmaceuticals	245.07	245.07
2	Trading in Securities	0	0
3	Laboratory Testing	185.7	185.7
	<b>Total Segment Liabilities</b>	430.77	430.77
	<b>Un-allocable Liabilities</b>	6859.1	6859.1
	<b>Net Segment Liabilities</b>	7289.87	7289.87
	<b>Disclosure of notes on segments</b>		

